000 01779 a2200481 4500
005 20250518032521.0
264 0 _c20200324
008 202003s 0 0 eng d
022 _a1090-2104
024 7 _a10.1016/j.bbrc.2019.02.015
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHoshi, Taisuke
245 0 0 _aLenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
_h[electronic resource]
260 _bBiochemical and biophysical research communications
_c05 2019
300 _a1-7 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aCarcinoma, Hepatocellular
_xdrug therapy
650 0 4 _aCell Line, Tumor
650 0 4 _aFemale
650 0 4 _aFibroblast Growth Factors
_xmetabolism
650 0 4 _aHumans
650 0 4 _aLiver Neoplasms
_xdrug therapy
650 0 4 _aMAP Kinase Signaling System
_xdrug effects
650 0 4 _aMice
650 0 4 _aMice, Inbred BALB C
650 0 4 _aMice, Nude
650 0 4 _aPhenylurea Compounds
_xtherapeutic use
650 0 4 _aQuinolines
_xtherapeutic use
650 0 4 _aReceptors, Fibroblast Growth Factor
_xmetabolism
650 0 4 _aSignal Transduction
_xdrug effects
700 1 _aWatanabe Miyano, Saori
700 1 _aWatanabe, Hideki
700 1 _aSonobe, Regina Mikie Kanada
700 1 _aSeki, Yuki
700 1 _aOhta, Etsuko
700 1 _aNomoto, Kenichi
700 1 _aMatsui, Junji
700 1 _aFunahashi, Yasuhiro
773 0 _tBiochemical and biophysical research communications
_gvol. 513
_gno. 1
_gp. 1-7
856 4 0 _uhttps://doi.org/10.1016/j.bbrc.2019.02.015
_zAvailable from publisher's website
999 _c29548649
_d29548649